{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:50:43Z","timestamp":1791449443364,"version":"4.3.3"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019211","name":"AbbVie Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019211","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s13555-026-01907-7","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:39:32Z","timestamp":1789141172000},"page":"5195-5214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Evidence of Upadacitinib in Atopic Dermatitis after Inadequate Response or Intolerance to Dupilumab: The CAN\u00a0UpTIMISE Study"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8315-2522","authenticated-orcid":false,"given":"Vimal H.","family":"Prajapati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8926-0113","authenticated-orcid":false,"given":"Melinda J.","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3468-8865","authenticated-orcid":false,"given":"Michael","family":"Cecchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9163-5463","authenticated-orcid":false,"given":"Charles W.","family":"Lynde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9296-5851","authenticated-orcid":false,"given":"Parbeer","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ferrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8568-0775","authenticated-orcid":false,"given":"David","family":"Pr\u00e9fontaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly","family":"Sterling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9963-8319","authenticated-orcid":false,"given":"H.","family":"Chih-ho Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"issue":"2","key":"1907_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.5021\/ad.2010.22.2.125","volume":"22","author":"T Bieber","year":"2010","unstructured":"Bieber T. Atopic dermatitis. Ann Dermatol. 2010;22(2):125\u201337. https:\/\/doi.org\/10.5021\/ad.2010.22.2.125.","journal-title":"Ann Dermatol"},{"issue":"3","key":"1907_CR2","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jaad.2015.10.043","volume":"74","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Eckert L, et al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016;74(3):491\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2015.10.043.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1907_CR3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.det.2017.02.002","volume":"35","author":"JI Silverberg","year":"2017","unstructured":"Silverberg JI. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin. 2017;35(3):283\u20139. https:\/\/doi.org\/10.1016\/j.det.2017.02.002.","journal-title":"Dermatol Clin"},{"issue":"4","key":"1907_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","volume":"126","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417-28.e2. https:\/\/doi.org\/10.1016\/j.anai.2020.12.020.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1907_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/12034754261431744","author":"MJ Gooderham","year":"2026","unstructured":"Gooderham MJ, Breslavets M, Turchin I, et al. Disease burden in a cohort of Canadian adults with moderate-to-severe atopic dermatitis by systemic therapy use. J Cutan Med Surg. 2026. https:\/\/doi.org\/10.1177\/12034754261431744.","journal-title":"J Cutan Med Surg"},{"issue":"24","key":"1907_CR6","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1610020.","journal-title":"N Engl J Med"},{"issue":"10086","key":"1907_CR7","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287\u2013303. https:\/\/doi.org\/10.1016\/S0140-6736(17)31191-1.","journal-title":"Lancet"},{"issue":"5","key":"1907_CR8","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"M de Bruin-Weller","year":"2018","unstructured":"de Bruin-Weller M, Thaci D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE). Br J Dermatol. 2018;178(5):1083\u2013101. https:\/\/doi.org\/10.1111\/bjd.16156.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1907_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","volume":"156","author":"M Worm","year":"2020","unstructured":"Worm M, Simpson EL, Thaci D, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(2):131\u201343. https:\/\/doi.org\/10.1001\/jamadermatol.2019.3617.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1907_CR10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40257-020-00527-x","volume":"21","author":"LA Beck","year":"2020","unstructured":"Beck LA, Thaci D, Deleuran M, et al. Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2020;21(4):567\u201377. https:\/\/doi.org\/10.1007\/s40257-020-00527-x.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"1907_CR11","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/bjd.18179","volume":"182","author":"LEM de Wijs","year":"2020","unstructured":"de Wijs LEM, Bosma AL, Erler NS, et al. Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data. Br J Dermatol. 2020;182(2):418\u201326. https:\/\/doi.org\/10.1111\/bjd.18179.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1907_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaad.2019.02.053","volume":"81","author":"S Faiz","year":"2019","unstructured":"Faiz S, Giovannelli J, Podevin C, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019;81(1):143\u201351. https:\/\/doi.org\/10.1016\/j.jaad.2019.02.053.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1907_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/ijd.14573","volume":"59","author":"C Wang","year":"2020","unstructured":"Wang C, Kraus CN, Patel KG, Ganesan AK, Grando SA. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients\u2019 records. Int J Dermatol. 2020;59(2):253\u20136. https:\/\/doi.org\/10.1111\/ijd.14573.","journal-title":"Int J Dermatol"},{"issue":"1","key":"1907_CR14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/all.14080","volume":"75","author":"LFM Ariens","year":"2020","unstructured":"Ariens LFM, van der Schaft J, Bakker DS, et al. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: first clinical and biomarker results from the BioDay registry. Allergy. 2020;75(1):116\u201326. https:\/\/doi.org\/10.1111\/all.14080.","journal-title":"Allergy"},{"issue":"1","key":"1907_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.anai.2020.07.026","volume":"126","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Guttman-Yassky E, Gadkari A, et al. Real-world persistence with dupilumab among adults with atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126(1):40\u20135. https:\/\/doi.org\/10.1016\/j.anai.2020.07.026.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"1907_CR16","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1177\/1203475420928907","volume":"24","author":"CE Jo","year":"2020","unstructured":"Jo CE, Georgakopoulos JR, Ladda M, et al. Short-term evaluation of the real-world efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis: a Canadian multicenter retrospective cohort study. J Cutan Med Surg. 2020;24(5):468\u201373. https:\/\/doi.org\/10.1177\/1203475420928907.","journal-title":"J Cutan Med Surg"},{"issue":"5","key":"1907_CR17","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1080\/09546634.2019.1682503","volume":"32","author":"MC Fargnoli","year":"2021","unstructured":"Fargnoli MC, Esposito M, Ferrucci S, et al. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat. 2021;32(5):507\u201313. https:\/\/doi.org\/10.1080\/09546634.2019.1682503.","journal-title":"J Dermatolog Treat"},{"issue":"7","key":"1907_CR18","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1001\/jamadermatol.2019.0109","volume":"155","author":"GA Zhu","year":"2019","unstructured":"Zhu GA, Chen JK, Chiou A, Ko J, Honari G. Assessment of the development of new regional dermatoses in patients treated for atopic dermatitis with dupilumab. JAMA Dermatol. 2019;155(7):850\u20132. https:\/\/doi.org\/10.1001\/jamadermatol.2019.0109.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1907_CR19","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/bjd.18730","volume":"183","author":"LEM de Wijs","year":"2020","unstructured":"de Wijs LEM, Nguyen NT, Kunkeler ACM, Nijsten T, Damman J, Hijnen DJ. Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series. Br J Dermatol. 2020;183(4):745\u20139. https:\/\/doi.org\/10.1111\/bjd.18730.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1907_CR20","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jaad.2019.06.026","volume":"82","author":"RA Waldman","year":"2020","unstructured":"Waldman RA, DeWane ME, Sloan B, Grant-Kels JM. Characterizing dupilumab facial redness: a multi-institution retrospective medical record review. J Am Acad Dermatol. 2020;82(1):230\u20132. https:\/\/doi.org\/10.1016\/j.jaad.2019.06.026.","journal-title":"J Am Acad Dermatol"},{"key":"1907_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jdcr.2020.10.023","volume":"7","author":"J Nguyen","year":"2020","unstructured":"Nguyen J, Chen JK, Honari G, Pol-Rodriguez M, Ko JM, Chiou AS. Bridging to a selective Janus kinase 1 inhibitor in severe atopic dermatitis: an instructive case with upadacitinib. JAAD Case Rep. 2020;7:65\u20137. https:\/\/doi.org\/10.1016\/j.jdcr.2020.10.023.","journal-title":"JAAD Case Rep"},{"issue":"2","key":"1907_CR22","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1111\/jdv.20221","volume":"39","author":"T Zhou","year":"2025","unstructured":"Zhou T, Al Muqrin A, Abu-Hilal M. Dupilumab and joint-related adverse effects: a systematic review. J Eur Acad Dermatol Venereol. 2025;39(2):e169\u201371. https:\/\/doi.org\/10.1111\/jdv.20221.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1907_CR23","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1080\/09546634.2022.2035309","volume":"33","author":"T Torres","year":"2022","unstructured":"Torres T, Paiva-Lopes MJ, Goncalo M, et al. Dupilumab for atopic dermatitis: a real-world Portuguese multicenter retrospective study. J Dermatolog Treat. 2022;33(5):2554\u20139. https:\/\/doi.org\/10.1080\/09546634.2022.2035309.","journal-title":"J Dermatolog Treat"},{"issue":"12","key":"1907_CR24","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","volume":"388","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Guttman-Yassky E, Thaci D, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388(12):1080\u201391. https:\/\/doi.org\/10.1056\/NEJMoa2206714.","journal-title":"N Engl J Med"},{"issue":"9","key":"1907_CR25","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047\u201355. https:\/\/doi.org\/10.1001\/jamadermatol.2021.3023.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1907_CR26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/bjd\/ljae404","volume":"192","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Bunick CG, Hong HC, et al. Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb\/IV study (Level Up). Br J Dermatol. 2024;192(1):36\u201345. https:\/\/doi.org\/10.1093\/bjd\/ljae404.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1907_CR27","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jaad.2023.05.033","volume":"89","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Ladizinski B, Prajapati VH, et al. Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up). J Am Acad Dermatol. 2023;89(3):478\u201385. https:\/\/doi.org\/10.1016\/j.jaad.2023.05.033.","journal-title":"J Am Acad Dermatol"},{"key":"1907_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-01003-0","author":"CG Bunick","year":"2026","unstructured":"Bunick CG, Magnolo N, Moore A, et al. Switching from dupilumab to upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis after inadequate response to dupilumab: efficacy and safety results from period 2 of phase 3b\/4 study (LEVEL UP). Am J Clin Dermatol. 2026. https:\/\/doi.org\/10.1007\/s40257-025-01003-0.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"1907_CR29","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jaad.2020.04.104","volume":"83","author":"E Simpson","year":"2020","unstructured":"Simpson E, Bissonnette R, Eichenfield LF, et al. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol. 2020;83(3):839\u201346. https:\/\/doi.org\/10.1016\/j.jaad.2020.04.104.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1907_CR30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1398-9995.2011.02719.x","volume":"67","author":"ME Schram","year":"2012","unstructured":"Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012;67(1):99\u2013106. https:\/\/doi.org\/10.1111\/j.1398-9995.2011.02719.x.","journal-title":"Allergy"},{"issue":"1","key":"1907_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","volume":"10","author":"JM Hanifin","year":"2001","unstructured":"Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol. 2001;10(1):11\u20138. https:\/\/doi.org\/10.1034\/j.1600-0625.2001.100102.x.","journal-title":"Exp Dermatol"},{"issue":"5","key":"1907_CR32","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/bjd.13662","volume":"172","author":"YA Leshem","year":"2025","unstructured":"Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2025;172(5):1353\u20137. https:\/\/doi.org\/10.1111\/bjd.13662.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1907_CR33","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/bjd.12290","volume":"169","author":"J Rhodes","year":"2013","unstructured":"Rhodes J, Clay C, Phillips M. The surface area of the hand and the palm for estimating percentage of total body surface area: results of a meta-analysis. Br J Dermatol. 2013;169(1):76\u201384. https:\/\/doi.org\/10.1111\/bjd.12290.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1907_CR34","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/bjd.15641","volume":"177","author":"R Chopra","year":"2017","unstructured":"Chopra R, Vakharia PP, Sacotte R, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol. 2017;177(5):1316\u201321. https:\/\/doi.org\/10.1111\/bjd.15641.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1907_CR35","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjd.17744","volume":"181","author":"G Yosipovitch","year":"2019","unstructured":"Yosipovitch G, Reaney M, Mastey V, et al. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761\u20139. https:\/\/doi.org\/10.1111\/bjd.17744.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1907_CR36","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1111\/j.1365-2133.2008.08832.x","volume":"159","author":"MK Basra","year":"2008","unstructured":"Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159(5):997\u20131035. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08832.x.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1907_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000365390","volume":"230","author":"MK Basra","year":"2015","unstructured":"Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology (Basel). 2015;230(1):27\u201333. https:\/\/doi.org\/10.1159\/000365390.","journal-title":"Dermatology (Basel)"},{"issue":"6","key":"1907_CR38","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/bjd.12590","volume":"169","author":"CR Charman","year":"2013","unstructured":"Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol. 2013;169(6):1326\u201332. https:\/\/doi.org\/10.1111\/bjd.12590.","journal-title":"Br J Dermatol"},{"issue":"12","key":"1907_CR39","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1001\/archderm.140.12.1513","volume":"140","author":"CR Charman","year":"2004","unstructured":"Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients\u2019 perspective. Arch Dermatol. 2004;140(12):1513\u20139. https:\/\/doi.org\/10.1001\/archderm.140.12.1513.","journal-title":"Arch Dermatol"},{"issue":"11","key":"1907_CR40","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1111\/jdv.20229","volume":"38","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Gooderham M, Katoh N, et al. Combining treat-to-target principles and shared decision-making: international expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol. 2024;38(11):2139\u201348. https:\/\/doi.org\/10.1111\/jdv.20229.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Supplement_2","key":"1907_CR41","doi-asserted-by":"publisher","first-page":"ii60","DOI":"10.1093\/bjd\/ljad498.063","volume":"190","author":"LF Eichenfield","year":"2024","unstructured":"Eichenfield LF, Grada A, Knapp KD, Munoz B, Crawford JM, Silverberg JI. 568 - Persistent inadequate disease control and therapeutic inertia in moderate-to-severe atopic dermatitis: a 12-month longitudinal analysis of real-world outcomes from TARGET-DERM registry. Br J Dermatol. 2024;190(Supplement_2):ii60\u20131. https:\/\/doi.org\/10.1093\/bjd\/ljad498.063.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1907_CR42","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1089\/derm.2024.0191","volume":"36","author":"DZ Eichenfield","year":"2025","unstructured":"Eichenfield DZ, Knapp KD, Claxton A, et al. Unmet needs of effective advanced systemic therapies in moderate-to-severe atopic dermatitis patients in the TARGET-DERM AD registry. Dermatitis. 2025;36(3):244\u201357. https:\/\/doi.org\/10.1089\/derm.2024.0191.","journal-title":"Dermatitis"},{"issue":"8","key":"1907_CR43","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1007\/s13555-025-01469-0","volume":"15","author":"JI Silverberg","year":"2025","unstructured":"Silverberg JI, Gooderham M, Wollenberg A, et al. Impact of achieving optimal treatment targets and minimal disease activity on health-related quality of life and satisfaction in patients with atopic dermatitis. Dermatol Ther (Heidelb). 2025;15(8):2255\u201373. https:\/\/doi.org\/10.1007\/s13555-025-01469-0.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1907_CR44","doi-asserted-by":"publisher","first-page":"AB78","DOI":"10.1016\/j.jaad.2024.07.320","volume":"91","author":"B de Nicolas-Ruanes","year":"2024","unstructured":"de Nicolas-Ruanes B, Berna-Rico E, Garcia-Mouronte E, et al. 52132 Real-world experience of switching atopic dermatitis treatment to upadacitinib after primary or secondary dupilumab failure. J Am Acad Dermatol. 2024;91(3):AB78.","journal-title":"J Am Acad Dermatol"},{"key":"1907_CR45","doi-asserted-by":"publisher","first-page":"adv00872","DOI":"10.2340\/actadv.v103.5243","volume":"103","author":"CM Boesjes","year":"2023","unstructured":"Boesjes CM, Van der Gang LF, Zuithoff NPA, et al. Effectiveness of upadacitinib in patients with atopic dermatitis including those with inadequate response to dupilumab and\/or baricitinib: results from the BioDay registry. Acta Derm Venereol. 2023;103:adv00872. https:\/\/doi.org\/10.2340\/actadv.v103.5243.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"1907_CR46","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.jaad.2023.08.059","volume":"89","author":"JR Georgakopoulos","year":"2023","unstructured":"Georgakopoulos JR, Sheka D, Rankin B, et al. Real-world effectiveness and safety of upadacitinib for the treatment of atopic dermatitis in adult patients switched from dupilumab: a multicenter retrospective study. J Am Acad Dermatol. 2023;89(6):1308\u201311. https:\/\/doi.org\/10.1016\/j.jaad.2023.08.059.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1907_CR47","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1093\/ced\/llaf253","volume":"50","author":"F Barei","year":"2025","unstructured":"Barei F, Chiei-Gallo A, Narcisi A, et al. Effectiveness and safety of upadacitinib in patients with moderate-to-severe atopic dermatitis and prior inefficacy of T helper 2 biologics: a propensity score-matched study. Clin Exp Dermatol. 2025;50(11):2153\u201362. https:\/\/doi.org\/10.1093\/ced\/llaf253.","journal-title":"Clin Exp Dermatol"},{"key":"1907_CR48","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70172","author":"CG Bunick","year":"2025","unstructured":"Bunick CG, Irvine AD, Silverberg JI, et al. Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years. J Eur Acad Dermatol Venereol. 2025. https:\/\/doi.org\/10.1111\/jdv.70172.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01907-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01907-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01907-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:00:33Z","timestamp":1791446433000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01907-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1907"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01907-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"16 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Vimal H. Prajapati has been an adviser, consultant, and\/or speaker for: AbbVie, Actelion, Amgen, Apogee Therapeutics, Aralez, Arcutis, Aspen, Bausch Health, BioJAMP\/JAMP Pharma, BioScript Solutions, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Cipher, CorEvitas, Eczema Society of Canada, Eli Lilly, Galderma, GlaxoSmithKline, Homeocan, Incyte, J&J Innovative Medicine, Janssen, Johnson & Johnson, LEO Pharma, Medexus, Novartis, Organon, Paladin, Pediapharm, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, Tribute, and UCB; served as an investigator for: AbbVie, AnaptysBio, Apogee Therapeutics, Apollo Therapeutics, Arcutis, Arena, Asana, Bausch Health, Bluefin, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CorEvitas, Dermavant, Dermira, Eli Lilly, Galderma, Incyte, J&J Innovative Medicine, Janssen, Kymera, LEO Pharma, Nektar Therapeutics, Nimbus Lakshmi, Novartis, Pfizer, RAPT Therapeutics, Regeneron, Reistone, Roche, Sanofi Genzyme, Sun Pharma, Takeda, UCB, and Vyne Therapeutics; and received grants from: AbbVie, Bausch Health, Janssen, LEO Pharma, Novartis, and Sanofi Genzyme. Vipul Jain has consulted as\/or advised and\/or received research funding from Allakos, Pediapharm\/Medexus, Sanofi\/Regeneron, Bausch, Novartis, AbbVie, Aralez, ALK, Celgene, Amgen, Leo Pharma, Mylan, Pfizer, Covis Pharma, Galderma, Eli Lilly, GSK, Kymab, Arcutis Biotherapeutics, Incyte, and AstraZeneca; is a primary investigator with Probity Medical Research and Director with Allergy Research Canada Inc. Melinda J. Gooderham served as an advisory board member of AbbVie, Amgen, Arcutis, Boehringer Ingelheim, BMS, Eli Lilly, Galderma, Incyte, Janssen, Leo Pharma, Novartis, Pfizer, Regeneron, Sanofi Genzyme, and UCB; served as a member of a speakers bureau for AbbVie, Amgen, Arcutis, Boehringer Ingelheim, BMS, Eli Lilly, Galderma, Incyte, Janssen, Leo Pharma, Novartis, Pfizer, Sanofi Genzyme, and UCB; received grant from AbbVie, Amgen, Akros, Arcutis, Aristea, Bausch Health, BMS, Boehringer Ingelheim, Celgene, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Incyte, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Merck, Moonlake, Nimbus, Novartis, Pfizer, Regeneron, Reistone, Roche, Sanofi Genzyme, Sun Pharma, and UCB; and participated in a clinical trial within the past 2\u00a0years for AbbVie, Amgen, Akros, Arcutis, Aristea, Bausch Health, BMS, Boehringer Ingelheim, Celgene, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Incyte, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Merck, Moonlake, Nimbus, Novartis, Pfizer, Regeneron, Reistone, Roche, Sanofi Genzyme, Sun Pharma, Takeda, Tarsus, UCB, and Vyne. Michael Cecchini has been an investigator and\/or consultant and\/or has been a speaker for AbbVie, Amgen, Arcutis, Bausch Health, Bluefin, BioJAMP, BMS, Boehringer Ingelheim, Celltrion, Eli Lilly, Fresenius-Kabi, Galderma, Incyte, Insmed, Janssen, Kyowa Kirin, Leo Pharma, Merck, Novartis, Pfizer, Pierre Fabre, Reistone, Sandoz, Sanofi, Sun Pharma, Takeda, UCB, Viatris. Jason K. Lee has consulted as\/or advised and\/or received research funding from Allakos, Pediapharm\/Medexus, Sanofi\/Regeneron, Bausch, Novartis, AbbVie, Aralez, ALK, Celgene, Amgen, Upstream Bio, Mylan, Celltrion, GSK, Incyte, and AstraZeneca. Charles W. Lynde has been a speaker and\/or consultant and\/or principal investigator for AbbVie, Acelyrin, Akros, Altius, Amgen, Apogee, Aralez, Arcutis, Avillion, Bausch Health, Bayer, Bioderma, BioJAMP, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celldex, Celltrion, CeraVe, Cipher, Concert, Dermavant, Dermira, Devonian, DICE, Eli Lilly, Endo, Evelo, Fresnius Kabi, Galderma, GSK, InCyte, Innovaderm, Intega Skin, Janssen, Kyowa Kirin, La Roche Posay, LEO Pharma, L\u2019Oreal, MC2, Medexus, MedX, Merck, MoonLake, Naos, Nimbus, Nektar, Novartis, Organon, Oruka, P&G, Paladin, Pediapharm, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sandoz, Searchlight Pharma, Sentrex, SkinCeuticals, SunPharma, Takeda, UCB, Viatris, Volo Health, Vyne. Parbeer Grewal served as an adviser, consultant, and\/or speaker for: AbbVie, Amgen, Anacor, Apogee therapeutics, Arcutis, Aspen Pharmaceuticals, Bausch Health, Boehringer Ingelheim, BMS, Celgene, Celltrion, Cipher, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Innovaderm, J&J\/Janssen, JAMP Pharma, Leo Pharma, Med Plan, Novartis, Pfizer, Regeneron, Sanofi-Aventis\/Genzyme, Sandoz, Sun Pharmaceuticals, Takeda, and UCB. Investigator for: AbbVie, Amgen, Anacor, Apogee, Arena Pharmaceuticals, Avillion, Bausch Health, Biogen, BMS, Boehringer Ingelheim, Celgene, CorEvitas, Dermavant, Eli Lilly, Galderma, Innovaderm, J&J\/Janssen, Leo Pharma, Meiji Seika Pharma, Moonlake Immunotherapeutics, Novartis, Pfizer, Regeneron, Sanofi-Aventis\/Genzyme, Sandoz, Takeda, UCB, and Vitae. Andrew Ferrier has been an investigator and\/or consultant and\/or received speaking fees from AbbVie, Amgen, Bausch Health, Bristol Meyers Squibb, Galderma, LEO Pharma, Sanofi Genzyme, Sun Pharma, and UCB. David Pr\u00e9fontaine and Carly Sterling are employees of AbbVie and may own AbbVie stock and\/or AbbVie stock options. H. Chih-ho Hong has been an investigator and\/or consultant and\/or received speaking fees from AbbVie, Amgen, Arcutis, ASLAN pharmaceutics, Bausch Health, Biocon, Boehringer-Ingelheim, Bristol Meyers Squibb, Celgene, Celltrion, Cutanea, Dermira, Dermavant, DS Biopharma, Eli-Lilly, Evelo Biosciences, Galderma, GSK, Incyte, Iqvia, JAMP Pharma, Janssen, Leo Pharma, Medimmune, Merck, Mirimar, Novartis, Organon, Oruka, Pfizer, Regeneron, Sanofi-Genzyme, Sun Pharma, Takeda, UCB.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation Guidelines for Good Clinical Practice and approved by institutional review board (IRB)\/independent ethics committees (central ethics committee: Advarra IRB #Pro00063117; refer to Supplementary Table\n                      \n                      for local ethics approval). All patients provided informed consent.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}